Showing results (2521-2530 of 3,353) with videos related to

Sort By:
Pageof 336
Pharmacoeconomics|January 31, 2009
Estimating the cost of diabetes mellitus-related events from inpatient admissions in Sweden using administrative hospitalization dataUlf-G Gerdtham, Philip Clarke, Alison Hayes, et al.
Pharmacoeconomics|October 13, 2010
Methods of model calibration: observations from a mathematical model of cervical cancerDouglas C A Taylor, Vivek Pawar, Denise Kruzikas, et al.
Pharmacoeconomics|April 2, 2011
Pharmacoeconomic considerations in treating iron overload in patients with β-thalassaemia, sickle cell disease and myelodysplastic syndromes in the US: a literature reviewBin Zhang, Prina Z Donga, Mitra Corral, et al.
Pharmacoeconomics|June 5, 2019
Mapping the PedsQL™ onto the CHU9D: An Assessment of External Validity in a Large Community-Based SampleChristine Mpundu-Kaambwa, Gang Chen, Elisabeth Huynh, et al.
Pharmacoeconomics|June 5, 2019
Valuation of EQ-5D-5L Health States in Poland: the First EQ-VT-Based Study in Central and Eastern EuropeDominik Golicki, Michał Jakubczyk, Katarzyna Graczyk, et al.
Pharmacoeconomics|July 31, 2016
The Pharmacoeconomic Evaluation Process in IrelandLaura McCullagh, Michael Barry
Pharmacoeconomics|May 13, 2015
Systematic Literature Review of the Methods Used to Compare Newer Second-Generation Agents for the Management of Schizophrenia: A focus on Health Technology AssessmentGregory Kruse, Bruce J O Wong, Mei Sheng Duh, et al.
Pharmacoeconomics|May 6, 2015
Costs to Health Services and the Patient of Treating Tuberculosis: A Systematic Literature ReviewYoko V Laurence, Ulla K Griffiths, Anna Vassall
Pharmacoeconomics|August 4, 2016
Estimating Marginal Healthcare Costs Using Genetic Variants as Instrumental Variables: Mendelian Randomization in Economic EvaluationPadraig Dixon, George Davey Smith, Stephanie von Hinke, et al.
Pharmacoeconomics|August 11, 2016
Olaparib for Maintenance Treatment of BRCA 1 or 2 Mutated, Relapsed, Platinum-Sensitive Ovarian, Fallopian Tube and Peritoneal Cancer in People Whose Relapsed Disease has Responded to Platinum-Based Chemotherapy: An Evidence Review Group Perspective of a NICE Single Technology AppraisalPaul Tappenden, Sue Harnan, Shijie Ren, et al.
Pageof 336